Table 2 Trend in absolute lymphocyte count according to patient and treatment characteristics
From: Sustained lymphocyte decreases after treatment for early breast cancer
Mean absolute lymphocyte count (×109/L) | Test for trend | |||||
|---|---|---|---|---|---|---|
Baseline | End of treatment | 3–6 m post chemo | >12 m post chemo | Slope | p-value | |
Menopausal status (n) | ||||||
Post-menopausal | 2.06 (106) | 1.19 (105) | 1.51 (68) | 1.84 (58) | −0.0785 | 0.04 |
Pre-menopausal | 2.04 (73) | 1.10 (70) | 1.26 (44) | 1.75 (41) | −0.1179 | <0.01 |
GnRH agonist | 1.97 (40) | 1.16 (38) | 1.29 (24) | 1.64 (22) | −0.1279 | 0.02 |
No GnRH agonist | 2.11 (33) | 1.04 (32) | 1.22 (20) | 1.88 (19) | −0.1064 | 0.05 |
Age (n) | ||||||
<43 | 2.08 (44) | 1.16 (40) | 1.28 (25) | 1.70 (24) | −0.1499 | <0.01 |
43–61 | 2.03 (91) | 1.11 (93) | 1.34 (60) | 1.72 (55) | −0.1078 | <0.01 |
>61 | 2.06 (44) | 1.25 (42) | 1.69 (27) | 2.15 (20) | 0.0065 | 0.93 |
Chemotherapy regimen (n) | ||||||
AC-T | 2.09 (158) | 1.13 (153) | 1.36 (104) | 1.77 (86) | −0.1249 | <0.01 |
AC without taxane | 1.83 (18) | 1.35 (18) | 2.02 (8) | 2.03 (12) | 0.1085 | 0.36 |
Non-anthracycline | 1.30 (3) | 1.25 (4) | – (0) | 2.1 (10) | 0.2714 | 0.54 |
Dose dense | 2.03 (60) | 1.11 (58) | 1.16 (40) | 1.40 (25) | −0.2509 | <0.01 |
Standard dose | 2.06 (119) | 1.18 (117) | 1.55 (72) | 1.94 (74) | −0.0343 | 0.31 |
Radiotherapy (n) | ||||||
Yes | 2.05 (147) | 1.16 (145) | 1.37 (100) | 1.68 (82) | −0.1325 | <0.01 |
No | 2.05 (32) | 1.12 (30) | 1.72 (12) | 2.40 (17) | 0.1051 | 0.16 |
